Welcome to our dedicated page for Recursion Pharmaceuticals news (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals stock.
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a clinical-stage biotechnology company revolutionizing the field of drug discovery. By integrating technological innovations across biology, chemistry, automation, data science, and engineering, Recursion aims to decode biology and industrialize the drug discovery process.
Founded with a vision to radically improve patient lives, Recursion has developed a powerful drug discovery platform capable of conducting millions of rapid, automated experiments. This platform leverages the Recursion Operating System (OS), a sophisticated data and machine learning infrastructure, to accelerate the discovery of therapeutics, especially for rare genetic diseases.
Recent achievements include pioneering the use of machine learning in predicting protein-ligand interactions and partnering with major pharmaceutical companies like Bayer and Enamine. These collaborations have significantly enhanced Recursion's capabilities in chemical space exploration and drug discovery.
Financially, Recursion is robust, constantly expanding its dataset and computational resources, including operating one of the world's most powerful supercomputers, BioHive-2. This supercomputer, equipped with NVIDIA DGX H100 systems, significantly enhances their ability to train AI models and accelerate drug discovery.
Headquartered in Salt Lake City and with offices in Toronto, Montréal, and the San Francisco Bay Area, Recursion is a founding member of BioHive, the Utah life sciences industry collective. The company's horizontal business model focuses on discovery, allowing for cost-efficient operations by spreading risks across various therapeutic opportunities.
Significant News:
- Partnership with Enamine: Recursion announced a partnership with Enamine to leverage its MatchMaker tool for enriched screening libraries.
- Agreement with Bayer: Recursion in-licensed a novel molecule for treating fibrotic diseases from its collaboration with Bayer.
- Launch of LOWE: Demonstrated LOWE, an LLM-based software for drug discovery tasks, in collaboration with NVIDIA.
- London Expansion: Opened a new office in London and appointed Michael Bronstein as a Scientific Advisor.
- First Quarter 2024 Financial Results: Reported significant progress and upcoming value catalysts in drug discovery and technology advancements.
- BioHive-2 Supercomputer: Launched BioHive-2, a top-tier supercomputer, to enhance AI model training and drug discovery processes.
- Nature Genetics Publication: Published findings on proximity bias in CRISPR-Cas9 editing and proposed a debiasing algorithm.
For more information, visit Recursion Pharmaceuticals or follow their updates on Twitter and LinkedIn.
Recursion (NASDAQ: RXRX) announced the initiation of two clinical trials: the Phase 2 TUPELO trial for REC-4881 targeting Familial Adenomatous Polyposis (FAP) and a Phase 1 trial for REC-3964 aimed at treating Clostridium difficile infection. The FAP trial, which has received Fast Track and Orphan Drug designations from the FDA, seeks to evaluate REC-4881’s efficacy in patients post-colectomy. REC-3964 is Recursion’s first in-house developed candidate entering clinical trials. In 2022, the company has now launched four clinical trials, showcasing ongoing progress despite industry challenges.
Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company, announced its participation in key investor conferences. The Morgan Stanley Global Healthcare Conference is set for September 12-14, 2022, followed by the Goldman Sachs Global Sustainability Forum on September 29, 2022. Recursion aims to industrialize drug discovery using its advanced platform, Recursion OS, which integrates vast biological and chemical datasets and powerful machine-learning algorithms. The company's cutting-edge approach enables it to conduct millions of experiments weekly, significantly enhancing drug development.
Recursion (RXRX) reported significant clinical and financial updates for Q2 2022, advancing multiple trials including Phase 2/3 for NF2-mutated meningiomas and a Phase 2 for Familial Adenomatous Polyposis (FAP). The FDA granted Fast Track and European Commission granted Orphan Drug designations for REC-4881, supporting its potential FAP treatment. Revenue rose to $7.7 million, up from $2.5 million in Q2 2021, driven by collaborations. However, R&D costs increased to $38.4 million, and the company reported a net loss of $65.6 million, overshadowing revenue growth.
Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company, announced its participation in the KeyBanc Technology Leadership Forum from August 8 to August 9, 2022. The company's innovative approach utilizes advanced machine learning and extensive biological datasets to transform drug discovery. Based in Salt Lake City, Recursion is a key player in the life sciences sector, significantly enhancing pharmaceutical research through its Recursion OS platform. For further information, visit www.recursion.com.
Recursion (NASDAQ: RXRX) announced that the European Commission granted Orphan Drug Designation for REC-4881, aimed at treating familial adenomatous polyposis (FAP). REC-4881 is a small molecule MEK1 and MEK2 inhibitor, designed to reduce polyp burden in FAP patients. Currently, there are no approved therapies for FAP, which affects about 50,000 patients in the US and Europe. This designation follows similar approvals by the FDA, helping to advance REC-4881 towards a Phase 2 clinical trial by the end of Q3 2022.
Recursion (NASDAQ: RXRX) has launched the Phase 2/3 POPLAR-NF2 clinical trial for REC-2282, targeting NF2-mutated meningiomas, a condition affecting approximately 33,000 patients annually. The trial, which is randomized and placebo-controlled, expects to enroll around 90 participants, assessing REC-2282's safety and efficacy. This compound has received both Fast Track and Orphan Drug designations from the FDA and the European Commission, positioning it as a potential first-in-class treatment for these debilitating tumors.
Recursion (NASDAQ: RXRX), a biotechnology firm focused on drug discovery, announced its engagement in three upcoming investor conferences. These include the Jefferies Healthcare Conference from June 8 to June 10, 2022, the Goldman Sachs Annual Global Healthcare Conference from June 13 to June 16, 2022, and Morgan Stanley's Putting the Tech in Biotech Conference on June 28, 2022. The company utilizes advanced machine-learning algorithms to enhance drug discovery through its proprietary Recursion Operating System, expanding its extensive biological and chemical datasets.
Recursion (Nasdaq: RXRX) announced significant advancements in its clinical trials and financial results for Q1 2022. The company initiated dosing in its Phase 2 trial for cerebral cavernous malformation (CCM) and plans to start a Phase 2/3 trial for NF2-mutated meningiomas in Q2 2022. REC-4881 received Fast Track designation for familial adenomatous polyposis (FAP), with a Phase 2 trial set for Q3 2022. Financially, Q1 2022 revenues reached $5.3 million, up from $2.6 million year-over-year, although R&D expenses rose to $32.4 million, contributing to a net loss of $56.0 million.
Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company, has announced its participation in the Bank of America 2022 Healthcare Conference, taking place from May 10 to May 13, 2022. This event will showcase Recursion's innovative approach to drug discovery through its Recursion Operating System, which integrates advanced technologies and vast datasets. Recursion aims to transform medicine by leveraging machine learning and running millions of experiments weekly. Webcasts will be available on the company's investor website.
FAQ
What is the current stock price of Recursion Pharmaceuticals (RXRX)?
What is the market cap of Recursion Pharmaceuticals (RXRX)?
What is Recursion Pharmaceuticals, Inc.?
What is the Recursion OS?
What recent partnerships has Recursion announced?
What technological advancements has Recursion made?
What is the significance of the BioHive-2 supercomputer?
Where is Recursion Pharmaceuticals headquartered?
What is the focus of Recursion's drug discovery efforts?
How does Recursion's business model benefit its operations?
What is the role of machine learning in Recursion's platform?
How can I learn more about Recursion Pharmaceuticals?
